ACPC

Drug Profile

ACPC

Alternative Names: SYM 2030

Latest Information Update: 06 Nov 2006

Price : $50

At a glance

  • Originator National Institutes of Health (USA)
  • Class Antidepressants; Antiepileptic drugs; Antineoplastics; Neuroprotectants; Nootropics
  • Mechanism of Action Glycine NMDA-associated agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Stroke

Most Recent Events

  • 06 Nov 2006 Discontinued - Phase-II for Stroke (unspecified route)
  • 07 Oct 1998 A preclinical study has been added to the pharmacodynamics section
  • 10 Nov 1997 Phase-II clinical trials for Stroke (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top